- Thesis
- UnitedHealth's 2025 cost spike, mainly in Medicare Advantage, forced a guidance withdrawal and a CEO change. It left the market pricing the stock as though the business is still troubled. TheIn the second quarter of 2026, the medical care ratio has since improved for several straight quartersfell to 86.7% from 89.4% a year earlier, and management raised its 2026 guidance. But $860 million of favorable reserve changes from earlier periods helped that quarter. The case for a re-rating rests on that trend continuing rather than reversingthe ratio staying low without such help. It also rests on the outcome of the Department of Justice's investigation into Medicare Advantage billing. A large fine or a forced change to risk-coding practices would cut future revenue. A resolution with limited financial impact would remove a source of negative attention that has weighed on the stock since 20242025. New management is also selling down stakes in underperforming clinicsbringing partners into weak clinic businesses, such as a September 2026 dealpartnership with TPG for Florida clinics that became public in September 2026. ItOn October 1, 2026, it removed 30% ofabout 1,700 prior-authorization requirements on October 1codes, 2026which it calls about 30% of its requirements. For 2027, it also ends Medicare Advantage plans with about 390,000 members, to leave less profitable markets. BothThese steps are meant to show the business model still works without the practices under scrutiny. The next Q3 2026 results, due October 13, 2026, will show whether the medical care ratio keeps improving into the back half of the year. If it does, and the DOJ matter resolves without a severe penalty, the discount can close over the next two to four quarters. If a large fine or forced billing changes arrive instead, the market's caution would prove correct, and the stock could stay discounted well into 2027.
- Risks
- The Department of Justice is runninghas criminal and civil investigations into UnitedHealth's Medicare Advantage billing practices, which the company confirmed in July 2025. No settlement or charge was public on October 12, 2026. A Senate investigation published in January 2026 found evidencereport from the majority staff of Senator Grassley says that the company used home visits and chart reviews to add diagnoses that increased its government payments. The company disputes the report. A large fine or forced change to these practices could reduce future revenue.
UnitedHealth's medical cost ratio was elevated through 2025 because new Medicare Advantage members cost more to treat than the company priced for. Government rate-setting and shifts in member mix can still push costs higher than planned in future years. Lower 2027 star ratings can also reduce bonus payments in 2028.
The killing of a UnitedHealthcare executiveCEO Brian Thompson in December 2024 triggeredcaused public anger at health insurers over claim denials and prior authorization. This raised the risk of new state or federal regulationrules on insurer practices, which could reduce UnitedHealth's margins. In October 2026, the Texas Attorney General started an investigation into denials of care.
- Balance sheet
- Cash: $31.5B
Debt: $73.3B
Net debt: $41.8B
Interest cover: 9.0×
Debt due within 12 months: $3.8B
Ratings: Moody's A2 (negative outlook), S&P A+ (negative outlook), Fitch A (negative outlook)
UnitedHealth borrows at the parent holding company, mostly through senior unsecured notes, but most of its cash sits in regulated insurance subsidiaries. These subsidiaries must keep minimum statutory capital and need state approval for large dividends. On June 30, 2026, only $1.1 billion of the $28.6 billion of cash was available for general corporate use. The parent itself held only $303 million of cash at December 31, 2025. In 2025, it put a net $535 million into these subsidiaries and received no netcash dividends from themsubsidiaries to the parent fell to $6.8 billion, from $19.3 billion in 2024. No commercial paper was outstanding at June 30, 2026. Debt was 41.2% of total capital at that date, down from 44.1% a year earlier. Management targets about 40% by the end of 2026. Interest cover is earnings from operations over interest expense in the first half of 2026. $21 billion of bank credit facilities back the commercial paper program, and they were undrawn at December 31, 2025. The $7 billion 364-day facility ends in November 2026. The debt does not put the business at risk. But the negative outlooks and the reliance onlower subsidiary dividends explain its choices in the first half of 2026. The company repaid $2.5 billion of debtnotes and kept buybacks to $2.3 billion of commercial paper. It paid $1.6 billion in cash for buybacks, and $2.0 billion more for forward contracts on July 1, 2026.
As of 2026-06-30.
- Checkpoints
- Oct 13, 2026: Q3 2026 results: medical care ratio trend. Pending. Watch: A medical care ratio that stays below the year-earlier level89.9% and confirmedin line with the full-year guide of about 88.1%, without large favorable reserve changes, and confirmed or raised guidance pass; a rise in the ratio above the guide or a guidance cut fails.
Jan 2027 (estimate): Full-year 2026 results and first 2027 earnings outlook. Pending. Watch: A 2027 outlook with earnings growth and debt to capital near 40% passes; a flat or lower outlook or new reserve charges fails.
2027 (estimate): Department of Justice Medicare Advantage billing investigation outcome. Pending. Watch: A settlement with a fine the company can pay from one quarter of cash flow and no forced change to risk coding passes; a large fine or forced coding changes fail.
- Recent events
- 2026-10-08: The government published the 2027 Medicare Advantage star ratings. Analysts at J.P. Morgan and Stephens estimate that the share of UnitedHealth members in plans with 4 stars or more fell to about 67%, from about 78%. The company did not give a figure and said the results agreed with its expectations. Star ratings set bonus payments for 2028.
2026-10-05: The Texas Attorney General started an investigation into UnitedHealthcare. The investigation looks at denials of care and alleged payments to nursing homes.
2026-10-02: A UnitedHealthcare spokesperson said it will endthat the Medicare Advantage plans it ends for 2027 that cover about 390,000 members. It is leaving markets where its plans are less profitable. Affected members can choose another plan from October 15 to December 31, 2026.
2026-10-01: UnitedHealthcare removed about 1,700 prior authorization codes, which it calls about 30% of its prior authorization requirements. Most of the codes are for most commercial, Medicare Advantage, Community Plan, Individual Exchange and Oxford plans. Only a small number are for Medicare Advantage plans.
2026-09-2930: UnitedHealthcare namedA federal judge reduced the CalPERS securities lawsuit against UnitedHealth to 5 of 48 challenged statements. The claims about the late 2024 asset sales continue. The judge dismissed the insider-trading claims against Andrew Witty and Stephen Hemsley, but the plaintiffs can file them again.
2026-09-28: Robert Hunter itssaid that he is now president of UnitedHealthcare. Hunter was CEO of UnitedHealthcare Government Programs. Tim Noel stays CEO of UnitedHealthcare.
2026-09-0924: UnitedHealth soldnamed Jodee Kozlak to a minority stake innew role of chief administrative officer, from September 28, 2026.
2026-09-09: The CFO said that Optum has a partnership with private-equity firm TPG for a group of Florida WellMed clinics, which focus on older patients, to private-equity firm. The partnership started in the past year. The company did not give the size or the value of TPG's stake. Optum keeps an ownership interest and stays in the localFlorida market.
2026-07-16: UnitedHealth reported Q2 2026 revenue of $112.0 billion. The medical care ratio improved to 86.7%, from 89.4% a year earlier, and managementwith help from $860 million of favorable reserve changes from earlier periods. Management raised full-yearits 2026 adjusted EPS guidance to $19.50 to $20.00.
2025-05-13: UnitedHealth withdrewsuspended its full-year 2025 earnings guidanceoutlook. CEO Andrew Witty stepped down, and Stephen Hemsley returned as CEO.